Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $7.01, for a total value of $26,168.33. Following the completion of the sale, the insider directly owned 4,275,693 shares of the company’s stock, valued at approximately $29,972,607.93. This trade represents a 0.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

• On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total value of $309,370.41.
• On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total value of $280,238.40.

Entrada Therapeutics Stock Performance

TRDA traded up $0.05 during midday trading on Monday, hitting $7.05. The stock had a trading volume of 450,412 shares, compared to its average volume of 325,154. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45. The business has a fifty day moving average of $7.08 and a 200 day moving average of $9.31. The company has a market cap of $274.51 million, a P/E ratio of -1.78 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. The business had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. On average, equities research analysts anticipate that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on TRDA shares. Roth Capital restated a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a report on Wednesday, August 12th. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Weiss Ratings downgraded Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Finally, Guggenheim dropped their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.75.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Odyssean LLC bought a new position in Entrada Therapeutics during the 2nd quarter valued at approximately $230,000. Nantahala Capital Management LLC bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $2,212,232. Public Employees Retirement System of Ohio bought a new stake in shares of Entrada Therapeutics in the 2nd quarter worth approximately $276,000. Bank of America Corp DE purchased a new position in shares of Entrada Therapeutics during the second quarter valued at approximately $426,000. Finally, 5AM Venture Management LLC purchased a new position in shares of Entrada Therapeutics during the second quarter valued at approximately $29,854,949. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.